ScripsAmerica Launches RapiMed To Beat Tylenol Meltaways
This article was originally published in The Tan Sheet
Executive Summary
ScripsAmerica Inc.’s new RapiMed line of orally dissolving pediatric painkillers seeks to beat McNeil Consumer Healthcare’s Tylenol Meltaways’ return to the market and steal share from private label by promising to melt faster, taste better and cost less. The products also address FDA dosing concerns and target Hispanic shoppers.
You may also be interested in...
Business & Finance In Brief: GSK | MJN | Actavis | ScripsAmerica
GSK spotlights oral care; Mead Johnson weighs China pricing effects; USANA builds on Asia enthusiasm; FMC lands omega-3 firm Epax; Actavis eyes additional M&A activity; ScripsAmerica grows OTC and Rx distribution.
Business & Finance In Brief: GSK | MJN | Actavis | ScripsAmerica
GSK spotlights oral care; Mead Johnson weighs China pricing effects; USANA builds on Asia enthusiasm; FMC lands omega-3 firm Epax; Actavis eyes additional M&A activity; ScripsAmerica grows OTC and Rx distribution.
McNeil Recalls Liquid Infants’ Tylenol With Dosing Device Problem
McNeil Consumer Healthcare recalls an Infants’ Tylenol product that returned to market in November, after receiving consumer complaints about a problem with the SimpleMeasure dosing device system. The recall marks a misstep in the J&J subsidiary’s comeback from OTC quality control issues.